NSG 520 Unit 1 cellular mechanism trace example

From the Proximal Tubule's Glucose Transporter to Protein in the Urine: Tracing Diabetic Kidney Disease in One Patient

Student Name

Department of Nursing, Herzing University

NSG 520: Pathophysiology and Pharmacology

Instructor Name

January 21, 2026

From the Proximal Tubule's Glucose Transporter to Protein in the Urine: Tracing Diabetic Kidney Disease in One Patient

The Patient and the Finding

Mrs. D., a composite patient of 68, has lived with type 2 diabetes since age 54 and with high blood pressure since 58. At her annual visit, a serum creatinine of 1.5 mg/dL translates to an estimated filtration rate near 38 mL/min/1.73 m2 by the current race-free equation (Inker et al., 2021), and her urine shows 420 mg of albumin per gram of creatinine, well above the normal threshold of 30 mg/g. Her glycated hemoglobin is 7.6%, and her blood pressure is 142/84 on lisinopril. The finding a clinician notices is albumin in the urine with a falling filtration rate: diabetic kidney disease. This trace starts at one transporter in one segment of the nephron and follows the chain outward to that finding.

Step 1: The Starting Event at the Sodium-Glucose Cotransporter

In the early proximal convoluted tubule, the S1 segment, sodium-glucose cotransporter 2 reabsorbs about 90% of the glucose filtered by the glomerulus, moving one sodium ion into the cell with each glucose molecule, driven by the low intracellular sodium maintained by the basolateral sodium-potassium pump. In chronic hyperglycemia, more glucose is filtered, and the tubule responds by increasing its capacity to reabsorb it; expression and activity of the transporter rise. The result is increased reabsorption of both glucose and sodium in the proximal tubule. This is the starting event: a transporter working harder because of what it is handed.

Step 2: Less Sodium Reaches the Macula Densa

Because more sodium is reclaimed early in the nephron, less sodium chloride arrives at the macula densa, the specialized cells of the distal tubule where it passes the glomerulus of the same nephron. The macula densa senses sodium chloride delivery through a transporter on its luminal surface and uses it to regulate the glomerulus of its own nephron. This regulation is tubuloglomerular feedback.

Step 3: The Afferent Arteriole Dilates

When sodium chloride delivery falls, the macula densa interprets the signal as underfiltration. It reduces its release of adenosine, which normally constricts the afferent arteriole through adenosine A1 receptors. The afferent arteriole dilates. At the same time, angiotensin II, active in diabetes, constricts the efferent arteriole. Afferent dilation with efferent constriction raises the pressure inside the glomerular capillaries.

Step 4: Glomerular Hyperfiltration

Raised intraglomerular pressure increases the filtration rate of each nephron, a state called hyperfiltration. Early in diabetes, total glomerular filtration rate may even be above normal. Hyperfiltration is not benign: it subjects the glomerular capillary wall to sustained mechanical stress. A review of the mechanisms identifies increased proximal tubular reabsorption with reduced tubuloglomerular feedback as a central driver of hyperfiltration in diabetes, alongside the vascular effects of hormones such as angiotensin II (Tonneijck et al., 2017).

Step 5: The Filtration Barrier Is Damaged

The glomerular filtration barrier has three layers: the fenestrated endothelium, the glomerular basement membrane, and the podocytes, whose interdigitating foot processes form the final slit diaphragm. Sustained high pressure stretches and injures podocytes, which cannot divide to replace themselves; they detach and are lost. Meanwhile, chronic hyperglycemia damages the barrier through other paths: advanced glycation end products stiffen and thicken the basement membrane, and signaling through growth factors such as transforming growth factor beta drives mesangial expansion and matrix deposition. With podocytes lost and the basement membrane altered, the barrier becomes leaky to albumin.

Step 6: Albumin in the Urine, Then Falling Filtration

Albumin that crosses the damaged barrier appears in the urine, measured as the albumin-to-creatinine ratio: Mrs. D.'s 420 mg/g. Albumin in the tubular fluid is itself harmful, since tubular cells that reabsorb it are stressed and release inflammatory signals, promoting interstitial fibrosis. As glomeruli scar and nephrons are lost, the remaining nephrons hyperfilter further to compensate, which exposes them to the same injury. Over years, total filtration falls: her estimated rate of 38 places her in stage 3b chronic kidney disease, and her albuminuria places her in the highest albuminuria category. The finding the clinician notices is therefore the visible end of a chain that began at a transporter in the proximal tubule.

Other Inputs to the Same Chain in Mrs. D.

The trace follows one pathway, but Mrs. D.'s kidneys are exposed to several inputs that converge on the same glomerular injury. Her systemic hypertension adds to the pressure transmitted to the glomerular capillaries, especially if autoregulation at the afferent arteriole is impaired, as it often is in long-standing diabetes. Her age brings a gradual loss of nephrons, so each remaining nephron carries more of the filtering load, which is another route to hyperfiltration. Obesity, if present, raises filtration demand further. And the intermittent use of nonsteroidal anti-inflammatory drugs for arthritis pain, which she mentioned at her visit, reduces prostaglandin-mediated afferent dilation and can cause sudden falls in filtration on top of the chronic process. Each of these is worth naming because each can be modified: blood pressure to target, weight, and avoiding nonsteroidal drugs. The chain from the transporter to albuminuria explains why her kidney disease developed; the other inputs explain why it progressed at the pace it did, and they point to parts of her care that do not require a new prescription.

Why the Chain Matters for Treatment

Two links in the chain can be interrupted by drugs. Drugs that block the renin-angiotensin system, such as ACE inhibitors and angiotensin receptor blockers, reduce efferent constriction, lowering intraglomerular pressure, which is why Mrs. D. takes lisinopril. Sodium-glucose cotransporter 2 inhibitors act at the starting event: by blocking the transporter, they increase sodium delivery to the macula densa, restore tubuloglomerular feedback, constrict the afferent arteriole, and reduce hyperfiltration. The initial small fall in filtration rate after starting such a drug is the expected sign of that pressure falling. Understanding the trace explains why a drug introduced to lower glucose now protects the kidney even in patients whose glucose is well controlled. Tight glucose control reduces the input to the chain, but by itself it does not correct the altered feedback. The current international kidney guideline for diabetic patients therefore recommends both a renin-angiotensin system blocker and a sodium-glucose cotransporter 2 inhibitor for most patients like Mrs. D., each acting on a different link (Rossing et al., 2022).

References

Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Gutiérrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., ... Levey, A. S. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737-1749. https://doi.org/10.1056/NEJMoa2102953

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., & de Boer, I. H. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017). Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. Journal of the American Society of Nephrology, 28(4), 1023-1039. https://doi.org/10.1681/ASN.2016060666